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We recently published a next generation frame-
work for assessing the risk of genomic damage via
exposure to chemical substances. The framework
entails a systematic approach with the aim to quan-
tify risk levels for substances that induce genomic
damage contributing to human adverse health out-
comes. Here, we evaluated the utility of the frame-
work for assessing the risk for industrial chemicals,
using the case of benzene. Benzene is a well-
studied substance that is generally considered a
genotoxic carcinogen and is known to cause leuke-
mia. The case study limits its focus on occupational
and general population health as it relates to ben-
zene exposure. Using the framework as guidance,
available data on benzene considered relevant for
assessment of genetic damage were collected.
Based on these data, we were able to conduct
quantitative analyses for relevant data sets to
estimate acceptable exposure levels and to char-
acterize the risk of genetic damage. Key observa-
tions include the need for robust exposure
assessments, the importance of information on
toxicokinetic properties, and the benefits of che-
minformatics. The framework points to the need
for further improvement on understanding of the
mechanism(s) of action involved, which would also
provide support for the use of targeted tests rather
than a prescribed set of assays. Overall, this case
study demonstrates the utility of the next generation
framework to quantitatively model human risk on
the basis of genetic damage, thereby enabling a
new, innovative risk assessment concept. Environ.
Mol. Mutagen. 61:94–113, 2020. © 2019 The
Authors. Environmental and Molecular Mutagenesis published
by Wiley Periodicals, Inc. on behalf of Environmental Mutagen
Society.
Key words: human health riskassessment; genotoxicity;mutagenicity; exposure; testing strategy
INTRODUCTION
The testing of industrial chemicals for genetic damage has
long been a focus of regulatory examination (e.g., Dearfield
et al. 1991; Cimino 2006; EC 2008a; Eastmond et al. 2009;
Ji et al. 2017). The testing is usually tiered: The first tier con-
sists of a battery of genetic toxicity tests; any positive result
generally triggers in vivo testing on the same genotoxicity
endpoint. An in vivo positive result may lead to additional
testing. The conclusion for any genetic damage usually relies
on a yes/no binary decision (hazard identification) and does
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not examine the mechanism for the damage induced or char-
acterize the risk the damage may pose to humans under
exposure conditions.
Recent attention has focused on a paradigm shift that is
pushing to innovate chemical risk assessment, and new
concepts on how to achieve “next generation risk assess-
ment” have been proposed (NRC 2007; Krewski et al.
2010; Embry et al. 2014; Pastoor et al. 2014). These con-
cepts put more weight on exposure considerations com-
pared to current approaches and aim for integration of
sophisticated, preferably nonanimal, methods for hazard
characterization, using increased understanding of mecha-
nisms underlying toxicity as a starting point. Furthermore,
it has been recognized that a wider range of genomic dam-
age, including epigenetic alterations, is involved in many
adverse health outcomes. More detailed understanding of
mechanisms of genomic damage can play a key part in
understanding disease progression and/or susceptibility,
because genomic damage is now coupled to health issues
and diseases beyond cancer. Further, better mechanistic
understanding and assessment of genomic damage beyond
a hazard identification approach may allow identification of
levels below which exposure to a chemical poses negligible
risk for genomic damage, that is, a “point of departure”
(PoD) on the dose–response curve that can be utilized for
risk assessment and management. Thus, new approaches
that help unravel a broader range of mechanisms of action
leading to genomic damage are key to enable these more
information-rich risk assessment concepts.
The Health and Environmental Sciences Institute (HESI)
recently published a next generation framework for geno-
mic damage (Dearfield et al. 2017). The framework, devel-
oped by HESI’s Genetic Toxicology Technical Committee,
is a flexible and therefore, at least in principle, widely
applicable approach for assessing the risk of genomic dam-
age via exposure to chemical substances. The purpose of
the framework is to contribute to putting concepts for next
generation risk assessment into practice. It puts greater
emphasis on quantitative analyses and PoD determination
with a focus on risk of humans under exposure conditions.
Additionally, the approach aims to incorporate genomic,
and not only genetic, damage into the assessments of risk.
Hence, the approach is aimed at collecting information
required to determine the risk posed by genomic damage,
including estimates of risk.
The utility of the approach presented in Dearfield et al.
(2017) for industrial chemicals was evaluated, using ben-
zene as a case. The objective was to determine how the
accumulated data (traditional genetic toxicity studies and
other toxicity studies) could have been used following the
more flexible framework to better assess the genotoxic haz-
ard, characterize the risk of genetic damage, and possibly
identify a PoD from any genetic damage observed. Thus,
the emphasis of the case study was on the utility of the
framework, and explicitly not to produce another detailed
review manuscript on benzene. As this is the first time the
framework is evaluated, we chose to limit the case study to
genetic damage and not yet broaden the scope to genomic
damage.
Benzene is a naturally occurring substance. During com-
bustion processes, wood fires, and volcano eruptions,
increased concentrations of benzene in ambient air can be
measured. Benzene has been produced by humans since the
1800s from coal tar and later from petroleum. It also occurs
naturally as a component of petroleum and of condensate
from natural gas production, which is why many petroleum
products contain residues of benzene. To date, benzene is still
one of the most produced substances worldwide. Benzene is
used primarily as a synthesis intermediate in the chemical
and pharmaceutical industries for manufacturing of organic
chemicals, such as styrene and cumene, and as an intermedi-
ate in the production of drugs, dyes, coatings, adhesives,
insecticides, and plastics (ATSDR 2007, 2015; DECOS
2014; Eastmond et al. 2014). It is also added to gasoline for
its octane-enhancing and anti-knocking properties (IARC
2012). Benzene was extensively used in industrial, profes-
sional, and consumer products as an organic solvent but was
replaced over the years by less toxic solvents to meet occupa-
tional regulatory standards (Weisel 2010). Occupational
human exposure to benzene has been associated with a range
of acute and long-term adverse health effects and diseases,
including acute myeloid leukemia (Schnatter et al. 2005; Gal-
braith et al. 2010; Khalade et al. 2010) and myelodysplastic
syndrome (Hayes et al. 1997; Schnatter et al. 2012; Collins
et al. 2015; Copley et al. 2017; Li and Schnatter 2018).
Benzene-exposed individuals may also exhibit other adverse
health effects such as hematotoxicity, which arises via multi-
ple mechanisms and may be particularly evident among
genetically susceptible subpopulations (Paustenbach et al.
1993; Snyder et al. 1993; Lan et al. 2004; Wang et al. 2012).
BENZENEASACASE STUDY
The framework outlined in Dearfield et al. (2017) details a
systematic examination of the reason(s) for genotoxicity test-
ing, that is, what is known about the chemical under scrutiny
and which data gaps need to be filled by testing to conclude
on the genotoxicity potential. In brief, the framework com-
prises nine steps; see Table I. The first step is planning and
scoping, with the aim to clarify the problem and how it may
be addressed. This is followed by the development of a
knowledge base by gathering the existing information. After
having created the biological argument, additional studies
(if required) are identified and performed to test that biologi-
cal rationale. Review of all the data leads to identification of
the mechanisms of genetic damage involved as well as the
dose at which the damage of concern is induced. The risk of
causing damage at a given dose could then be established
using actual (measured) or projected exposure data.
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The purpose of the benzene case study was to evaluate
the utility of the framework. More specifically, using the
wide range of data available for benzene, we aimed to iden-
tify which information is key, unnecessary, or possibly
misleading for decision making. For this, we conducted a
retrospective analysis by using available data relevant for
assessment of the potential of benzene to cause geno-
toxicity; Table I lists how the framework was applied. As
benzene is a case study to evaluate the framework, we
chose to mainly rely on data presented in review docu-
ments, such as those published by the Health Council of
the Netherlands (DECOS 2014) and the European
Chemicals Agency Committee for Risk Assessment
(ECHA 2018). The data collected were reviewed to evalu-
ate whether the framework led to the information needed
for assessing the genotoxicity and eventually regulatory
decision making. Studies in humans, such as in workers in
the petrochemical industry, are obviously highly useful in
the context of human health risk assessment. Nevertheless,
available data from human studies were not considered
here because this type of study would normally not be
available for a new substance under evaluation.
Planning and Scoping (IncludingAnticipated Exposure)
The main goal of the planning and scoping process is to
establish the reason(s) for testing, that is, to define the pur-
pose and scope of a risk assessment and the depth of the
analysis (USEPA 2000, 2014; NRC 2009; Solomon et al.
2016; UN 2017). Relevant regulation(s) must be considered
if an assessment is required for regulatory purposes. An
important part of the planning and scoping step is the prob-
lem formulation, the systematic process to guide and direct
what scientific questions need to be addressed in the risk
assessment for the chemical under study. While planning
and scoping outlines the broader questions to be addressed
(including logistics, costs, etc.), problem formulation
focuses on the more specific scientific questions regarding
the chemical’s potential to cause genomic damage relevant
for human risk.
For benzene, an assessment of its genotoxic risk is con-
sidered an important contribution toward the risk manage-
ment goal of protecting public health, assuming the
assessment would produce the information required for
decision making. In Europe, such a safety assessment per-
formed by the producers is mandatory for classified sub-
stances manufactured or imported over 10 tonnes per
annum because of the Registration, Evaluation, Authorisa-
tion and Restriction of Chemicals (REACH) regulation laid
down in European Commission regulation no. 440/2008
(EC 2008a). In the United States, the Environmental Pro-
tection Agency (U.S. EPA) is required to evaluate both
new and existing industrial chemicals and mixtures for their
health and environmental risks under the Toxic Substances
Control Act (TSCA) (USEPA 2019). New chemicals are
subjected to premanufacturing notification/significant new
use rules with higher regulatory scrutiny (TSCA Section 5)
and, where necessary for existing chemicals, additional
testing may be mandated to adequately assess their risks
(TSCA Section 4). Other legislations require assessment of
substances for specific situations but do not require infor-
mation themselves. These situations include, for example,
TABLE I. Framework for Next Generation Risk Assessment
Step
No. Process Benzene as case
1 Planning and
scoping (incl.
anticipated
exposure)
• Identify the relevant regulations in place
for benzene
• Determine the most likely exposure
route for benzene
• Determine the population group(s) of
concern
• Determine the category of anticipated
exposure
2 Determine
expected
exposure
• Identify potential sources of benzene
exposure for appropriate exposure route
• Determine expected pattern of exposure
• Estimate the level of benzene exposure
for the population group(s) of concern
3 Build
knowledge
base
• Collect information on ADME
• Collect information on physic-chemical
characteristics
• Chemoinformatics: generate data using
QSAR software tools; include
predictions on possible metabolites
• Collect available data from relevant in
vitro and in vivo toxicity studies
• Collect data for other types of toxicity
than genetic damage
• Collect mechanistic information
4 Create rational
biological
argument
• Based on the knowledge gathered
determine the potential of benzene for
induction of genomic damage. If so,
determine the most likely mechanism
underlying this potential
5 Select assays
and perform
them
Not applicable here as using published
studies for benzene
6 Review
results
Not applicable here as using published
studies for benzene
7 Select appropriate
point of
departure
• Based on the rational biological
argument identify relevant data set(s)
• Conduct quantitative analyses to derive
a PoD
8 Estimate
acceptable
levels for
endpoints of
human
relevance
• Determine whether it is appropriate to
use a nonlinear approach
• Using the derived PoD determine the
acceptable level of daily exposure for
the population group(s) of concern
9 Risk
characterization
• Estimate the risk for humans by
applying MOE approach and by
comparing exposure level to the
acceptable level of
daily exposure
Based on the framework described in Dearfield et al. (2017).
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classification and labeling, transport, storage conditions,
and evacuations in case of accidents. As these legislations
do not require information, the availability depends upon
the information requirements of the general legislation for
industrial chemicals. Therefore, the information provided
under the general industrial chemical legislation should also
be sufficient to allow a risk assessment for specific situa-
tions. Given the use of benzene as a synthesis intermediate
in various industrial processes and as a fuel additive,
workers as well as the general population are of most con-
cern, with inhalation as the most likely exposure route. It
should be noted that benzene being a volatile substance
may pose challenges to the assessment of its hazardous
properties, especially regarding in vitro test systems.
In the context of this case study, we focused on both
population groups, that is, on workers in various industries
(e.g., petrochemical and manufacturing industries), and on
the general population. According to the framework, cate-
gorization of anticipated exposure is proposed, ranging
from minimal to high exposure [see Dearfield et al. 2017
for details], to define an initial base set of genetic toxicity
testing assays. This base set may vary by category of expo-
sure and size of population exposed. Benzene would fall
into the “minimal/low exposure” category for workers in
most industrialized developed countries because benzene is
used primarily as a synthesis intermediate in (chemical)
production plants and at oil refineries. Furthermore, protec-
tive measures have significantly improved over the last sev-
eral decades, at least in Europe and Northern America. The
potential for broad exposure category is applicable for the
general population, because of widespread exposure due to
the use of cigarettes, fueling at petrol stations, and motor
vehicle emissions.
ExposureAssessment
The human exposure assessment defines the target popu-
lation and potentially susceptible individuals, as described
later. It also defines the most important exposure sources,
pathways, and routes. The assessment will identify the
magnitude of cumulative exposures based on their source/
activity, frequency, and duration. Relevance of the expo-
sure assessment for decision making will then depend on
the exposure profile and toxicological profile (including
kinetics) of the substance (Geraets et al. 2016; Haber et al.
2016). An exposure assessment provides an estimate as a
daily external or internal dose (using basic toxicokinetic
data), an air concentration over a specified duration, or a
dermal load. Exposures from several sources should be
taken into account in the final so-called aggregate exposure
assessment.
Workplace exposure to benzene, where environmental
concentrations of benzene are higher than in the general
environment, occurs in Europe and Northern America
mainly at oil refineries, drilling stations, and fueling
stations, while this also involves other types of industry
(eg, manufacturing) in other regions of the world (ATSDR
2007, 2015; Weisel 2010; Park et al. 2015). In addition to
the background level, peak exposures may occur during
maintenance and control, leaks, or other incidental releases.
The frequency of occurrence of those peaks and the longest
period without peaks is relevant for a risk assessment. Inha-
lation exposure is the predominant route for workers,
although direct skin contact with certain high-grade oils
may be a relevant source of systemic exposure. Long-term
exposure to relatively high levels of benzene, compared to
the low background level found in the general population,
has been observed for workers (Weisel 2010). In Europe,
long-term occupational exposure to benzene is usually in
the range of 0.05 ppm (0.16 mg/m3) to 0.1 ppm
(0.3 mg/m3), due to its classification as a human carcinogen
including a requirement to substitute benzene or minimize
worker exposure. However, higher exposures have been
reported for several tasks in the petrochemical industry
(ECHA 2018). It should be noted that the worker situation
in the European Union may not be representative of expo-
sures in other (developed) countries. In China, exposures to
benzene in the shoe manufacturing industry may even
exceed levels of 100 ppm, according to a literature review
(Wang et al. 2006; Weisel 2010).
The general population is exposed daily to relatively low
concentrations of benzene resulting from industrial emis-
sions and vehicle exhaust. In the European Union, the
maximum content of benzene in gasoline, added as an anti-
knocking agent, was limited in 1998 to 1% (v/v)
[EU Directive 98/70/EC relating to the quality of petrol
and diesel fuels; EC 1998]. Subsequently, benzene concen-
trations in urban areas have decreased. ECHA reports sev-
eral studies covering the 1990s to approximately 2015
where both urban and rural areas across Europe have been
monitored. Air concentrations can vary but are within the
range of <0.5 to 50 μg benzene/m3. To protect human
health, a limit value of 5 μg benzene/m3 (1.5 ppb) has been
set to improve air quality in the European Union (Directive
2008/50/EC (EC 2008b)); this limit value might still be
exceeded in some urban areas (ECHA 2018). In other
countries, exposures to benzene may be higher. Additional
exposures result from cigarette smoking or passive
smoking and refueling of vehicles (Wallace 1989; ATSDR
2007, 2015; ECHA 2018). Exposure to benzene in con-
sumer products (substances and mixtures) and toys is
restricted and is no longer considered a significant contrib-
utor within the European Union. Because cigarette smoke
is a large contributor to benzene exposure, it is worthwhile
to consider smokers separately from nonsmokers. Environ-
mental tobacco smoke (passive smoking) can be a signifi-
cant source of benzene exposure for nonsmokers (Wallace
1989). Arnold et al. (2013) state that smoking accounts for
about 90% of cigarette smokers’ exposure to benzene. Gor-
don et al. (2002) state that benzene concentrations in
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exhaled breath can be 10–20 times higher for cigarette
smokers, indicating that smokers experience peak expo-
sures every time they smoke a cigarette. The benzene con-
centration in air inside a closed test chamber was elevated
from a background level of 5 to 18 μg/m3 benzene after
two cigarettes were smoked. Burning incense increased
levels from 5 to 12, and even up to 205 μg/m3 benzene
(Tirler and Settimo 2015).
Absorption,Distribution,Metabolism, and Elimination
Characteristics
Information on each of the absorption, distribution,
metabolism, and elimination (ADME) components of
toxicokinetics is highly relevant to both exposure and haz-
ard assessment. Benzene is known to be readily absorbed
by all physiological routes, including inhalation. Studies of
the absorption of benzene after inhalation exposure have
been published showing mean absorption rates ranging
from approximately 50 to 80% (DECOS 2014). Data from
case studies suggest that benzene, upon absorption, is read-
ily distributed throughout the body. Benzene has been
detected in various biological fluids and tissues of humans
and has been shown to cross the human placenta. As ben-
zene is lipophilic, the highest levels have been detected in
lipid-rich tissues (DECOS 2014). Animal studies show sim-
ilar findings and also indicate that benzene distribution may
depend on the perfusion rate of tissues, with higher levels
being found in tissues with high perfusion rates, such as
the kidney, lung, liver, brain, and spleen (DECOS 2014).
The metabolism of benzene occurs predominantly in the
liver but also in the lung, with secondary metabolism
occurring in the bone marrow (McHale et al. 2012). In
brief, the metabolism of benzene starts with oxidation to
benzene oxide mainly by cytochrome P450 2E1
(CYP2E1). Benzene oxide spontaneously rearranges to
phenol, which subsequently results in catechol and/or
hydroquinone metabolites, both of which can be addition-
ally converted into toxic metabolites (Meek and Klaunig
2010). Alternatively, benzene oxide may be further metab-
olized to benzene dihydrodiol, which can be converted to
catechol (Meek and Klaunig 2010; DECOS 2014). There is
also the potential for a ring opening of the benzene leading
to the formation of aldehyde metabolites. Inactivation
occurs for example by an enzymatic reaction with glutathi-
one. Some of the metabolites accumulate in the bone mar-
row where myeloperoxidases and other heme-protein
peroxidases further activate phenolic metabolites to
semiquinone radicals producing reactive oxygen species,
which inflict oxidative damage in various stem and progen-
itor cells and bone marrow niches (Snyder and Hedli 1996;
Tuo et al. 1996; Hartwig 2010; McHale et al. 2012).
In the context of risk assessment, the complexity of ben-
zene’s metabolic properties is further increased due to genetic
polymorphisms that have been reported for enzymes involved
in benzene metabolism. These polymorphisms, including
CYP2E1, glutathione-S-transferases GSTM1, GSTT1, and
GSTP1, and NAD(P)H:quinone oxidoreductase 1, may influ-
ence both the toxification and detoxification of benzene
(Carrieri et al. 2018; ECHA 2018). At least some of the
reported polymorphisms seem to be associated with a higher
susceptibility of developing leukemia (ECHA 2018). Further-
more, Carbonari et al. (2016) have shown that variability in
polymorphic gene frequencies exists within and between
Caucasian, Asian, and African populations, especially regard-
ing GSTT1, GSTM1, and GSTA1.
Exhalation is the main route for excretion of unmetabolized
benzene, whereas metabolized benzene is excreted primarily via
urine (ATSDR 2007; ECHA 2018). Studies in humans and ani-
mals indicate that both exhalation and urinary excretion occur in
several phases, with half-lives of minutes to hours (ATSDR
2007). The half-life for the slow phase of benzene elimination
suggests an accumulation of benzene (ATSDR 2007).
HazardAssessment
In SilicoData
Computer-assisted (in silico) quantitative structure–
activity relationships (QSARs) and read-across/analog
identification methods provide predictions of the potential
toxicity of a substance and are commonly used to aid initial
assessment of hazard potential and prioritization for testing.
Their use as tools to address toxicity endpoints (as part of a
weight-of-evidence approach) for regulatory decision mak-
ing is increasing. The framework points to these tools as
excellent resources to relatively quickly provide insight to
possible toxicities in the initial examination of chemicals as
one builds the knowledge base for assessment. Examples
include predicting QSARs of bacterial mutagenicity for
impurities in pharmaceuticals, as defined in International
Conference on Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Human Use Guide-
line M7 (ICH 2014) and under the European REACH regu-
lation supporting the use of read-across, or determining
whether full or limited registration is needed for low-
tonnage substances. These recent developments have fueled
investment and improvements in (Q)SAR and read-across
approaches, which are both based on structural similarity
and/or the presence or absence of molecular features that
give alerts for a certain toxic property of a substance. In
that context, it is hypothesized that a substance with similar
key structural features to another chemical for which suffi-
cient toxicity data are available will also act via the same
mechanism of action and have similar toxicity potential. It
is important to note that this concept is usually applied only
if a substance has no actual testing data for a given end-
point but could provide important input into a weight-of-
evidence assessment to resolve questionable or conflicting
data and generates insights into potential mode(s) of action.
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There are numerous studies available for benzene that pro-
vide a comprehensive assessment of its genotoxicity. Conse-
quently, including (Q)SAR and/or read-across methods in
decision making may therefore not be an obvious choice. How-
ever, in the context of the evaluation of the utility of our next
generation framework (Dearfield et al. 2017), in silico informa-
tion is seen as an important building block to provide insight
into the potential for genotoxic mechanisms. We performed a
(Q)SAR and read-across evaluation for benzene and its relevant
analogs with a focus on genotoxicity endpoints. First, potential
analogs of benzene were identified using both Organization for
Economic Co-operation and Development (OECD) Toolbox
models and the analog search strategy as described by Wu et al.
(2010). The chemicals identified were then rated (Wu et al.
2010), resulting in five chemicals classified as “suitable with
precondition” (phenol, catechol, hydroquinone, benzene oxide,
and 1,2-dihydro-1,2-dihydroxybenzene; Table II), all of which
are metabolites of benzene. The precondition implies that the
metabolite does form in vivo, and thus internal (systemic) expo-
sure to these metabolites can be expected to occur. Next, ben-
zene and all suitable with precondition analogs were subjected
to a detailed QSAR analysis using Derek Nexus (version 6.0.1,
2018; Lhasa Limited, Leeds, UK) and OASIS Times (version
2.29.1.88; Laboratory of Mathematical Chemistry, Bourgas,
Bulgaria) software. It should be noted that benzene data were
not part of the training sets used for the development of these
tools. An overview of the predictions obtained with the two
software packages is provided in Table III, which also lists the
relevance of the prediction according to OASIS Times. Neither
benzene nor any of the five analogs themselves triggered an
alert for mutagenicity in bacteria or clastogenicity in in vitro
tests in these software tools. However, the tools indicated an
alert for clastogenicity in in vitro tests for metabolites of three
analogs (benzene oxide, catechol, hydroquinone), and an alert
for mutagenicity in bacteria for metabolites of benzene oxide.
Besides indicating potential for genetic damage, these results
suggest that the metabolism involved is complex. Also, the
alerts provide insight to which type of genetic tests
(clastogenicity here) would be useful in targeting testing for
potential genotoxic activity (i.e., more focused testing vs. a stan-
dard battery approach).
InVitroData
A wealth of information on in vitro testing of genetic
damage induced by benzene or its metabolites is available.
It should be noted that benzene is a volatile substance,
which generally is challenging to test appropriately in an
in vitro test system. Additionally, the use of S9 mix may
be inadequate to mimic in vitro the metabolic capacity
required for the complex metabolism of benzene. There-
fore, we chose not to collect data only for benzene itself,
but also for a limited set of metabolites. In light of the pur-
pose of the present case study, we focused on benzene and
the five metabolites that were predicted by in silico tools to
be of relevance for human exposure.
As shown in Table IV, benzene administration induced
micronuclei (MN) in a Chinese hamster lung (CHL)/IU cell
line (Matsushima et al. 1999) as well as in MCL-5 cells;
however, no response was detected in human lymphoblast
AHH-1 cells (Crofton-Sleigh et al. 1993). In an inter-
laboratory validation study using V79 cells with one treat-
ment and one sampling time only, benzene was found to
produce negative results after three hours of exposure with
metabolic activation and a 21-hour recovery period (von
der Hude et al. 2000). It was argued that the use of
TABLE II. Overview of Analogs With a “Suitable With Precondition” Rating for Benzene
Structure CAS RN Chemical name Analog rating Description
108–95-2 Phenol Suitable with precondition Predominant urinary
metabolite of benzene
120-80-9 Catechol Suitable with precondition Metabolite of benzene
123-31-9 Hydroquinone Suitable with precondition Metabolite of benzene
1488-25-1 Benzene oxide Suitable with precondition Epoxidation metabolite
of benzene
75453-80-4 1,2-Dihydro-1,2-dihydroxybenzene Suitable with precondition Metabolite of benzene
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dimethylsulfoxide as solvent, which reduces the metabo-
lism of benzene, and the short recovery period used in the
test were factors responsible for the negative response. On
the other hand, induction of MN was observed in a geneti-
cally engineered V79-derived cell line expressing both
human CYP2E1 and human sulfotransferase SULT1A1
(Jiang et al. 2014), confirming the key role of CYP2E1 and
Phase II enzymes in the metabolism of benzene and pro-
duction of active metabolites.
Data on chromosome aberrations and sister chromatid
exchange (SCE) are also summarized in Table IV. For the
chromosome aberration test in vitro, an overall negative
result was reported in the U.S. National Toxicology Program
(NTP) database after exposure to 16–1000 μg/mL, while
there was positive evidence for SCE in Chinese hamster
ovary (CHO) cells in the absence of S9 (Gulati et al. 1989).
A clastogenic response to benzene has been observed in
human lymphocytes, which also showed a significant
increase of aneuploidy in the absence of rat liver S9 (Ishidate
Jr. et al. 1988). When metabolic activation systems were
included, benzene has been reported positive in other types
of cells as well, including CHL and CHO cells (Ishidate
Jr. 1985; Ishidate Jr. et al. 1988). Numerical aberrations were
confirmed in other studies showing aneuploidy in the near
diploid range of Syrian hamster embryo cells (Tsutsui et al.
1997). A significant dose-dependent increase in cells with
chromosomal aberrations was observed more recently in cul-
tured bovine peripheral lymphocytes (Sivikova et al. 2005).
In the Ames test, benzene has been consistently classi-
fied as a nonmutagen (Table IV). Within the range of
1.5–1000 μg/plate, benzene was tested in standard strains
TA97, TA98, TA100, and TA1535 with and without meta-
bolic activation using both the Aroclor-induced male
Sprague–Dawley rat liver S9 mix and the male Syrian ham-
ster liver S9 mix. Despite a slight toxicity at the highest
concentration tested and an increase (although not dose-
dependent) in revertants in TA97, the overall outcome in
the NTP database is negative (NTP 2019). A number of
other studies and reviews reported similar conclusions
(Baker and Bonin 1985; Rexroat and Probst 1985; Zeiger
and Haworth 1985; Brams et al. 1987; Jung et al. 1992;
Muller et al. 1993; Kirkland et al. 2005, 2011). The non-
mutagenicity of benzene in bacteria has been linked to the
inadequacy of the S9 microsomal activation system
(Yardley-Jones et al. 1991). In fact, it was reported that
Aroclor was not able to induce the P450 enzymes involved
in the biotransformation of benzene into active mutagenic
products. However, Burke et al. (1994) reported negative
results also in TA102 in the presence of inducers of
CYP2E1. Additional metabolic pathways in bacteria were
then suggested. A positive, but not dose-dependent, result
was reported only in TA1535 in the presence of NADPH-
fortified post-mitochondrial fractions (S9 mix) from rat and
mouse liver homogenates using a protocol with a desiccator
(Glatt et al. 1989).
In gene mutation tests in mammalian cells, benzene has
been repeatedly observed to induce gene forward mutations
in the L5178Y Tk+/− mouse lymphoma assay (MLA)
(Oberly et al. 1985; Styles et al. 1985; Oglesby et al. 1989;
Sofuni et al. 1996; Mitchell et al. 1997; Kirkland et al.
2005, 2011). Instead, no increase of such mutations was
reported in the NTP database (NTP 2019). By contrast,
results obtained for the Hprt locus were predominantly
negative, as reported by many authors (Amacher and
Turner 1985; Fox and Delow 1985; Kuroda 1985;
Zdzienicka and Simons 1985; Oberly et al. 1990). Only
Tsutsui et al. (1997) reported positive results for the Hprt
locus. The overall positive findings in the MLA and overall
negative Hprt data support a predominantly clastogenic
effect of benzene, as the induction of small colonies due to
slow growing mutants in the MLA is considered indicative
of clastogenicity rather than a point mutation (OECD
2015). On the other hand, other experts considered the
results for benzene uninterpretable upon review (Kirkland
et al. 2011; Schisler et al. 2018).
Taken together, we concluded that benzene has the
potential to induce clastogenic and possibly aneugenic
effects, while the evidence for its potential to induce gene
mutations is poor (Table IV). This conclusion is based on
the data presented and not on all studies available; how-
ever, it is in line with a recent assessment of ECHA’s Risk
Assessment Committee (RAC) (ECHA 2018). Remarkably,
benzene induced chromosome aberrations in the presence
of S9 in mammalian cells, while in bacteria the lack of
response was attributed to inadequacy of S9. This high-
lights the need to explore relevant in vitro data for metabo-
lites of benzene. Evaluation of in vitro genotoxicity test
results for the five metabolites of benzene (see the “In Sil-
ico Data” section and Table II) revealed that these metabo-
lites, like the parent compound, do not induce a strong
mutagenic response in bacteria, except for some evidence
in specific strains, as in the case of 1,2-dihydro-
1,2-dihydroxybenzene (Table IV). Other in vitro gen-
otoxicity data (besides mutagenicity in bacteria) were not
available for benzene oxide. Positive findings have been
reported for genotoxicity in mammalian cells for the
remaining four metabolites: phenol, catechol, hydroquinone,
and 1,2-dihydro-1,2-dihydroxybenzene. The available data
suggest a clastogenic potential, as MN, chromosomal aberra-
tions, and SCEs have been observed at different dose levels
and conditions [Whysner et al. 2004, summarized in
Table IV]. These results do not imply automatic inclusion of
the assessment of genotoxic potential for all metabolites.
However, in cases where metabolism is suspected to be com-
plex, additional data on metabolites may aid in detailed
understanding of the mechanisms involved, like here for ben-
zene and its metabolites. The chemical nature, rate of forma-
tion, presence of limiting enzymes, and metabolic pathways
to which they belong in the various tissues may explain the
diversity of responses and potency observed across the
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different metabolites and may contribute to the genotoxicity
effects of the parent compound (Glatt et al. 1989; Whysner
et al. 2004; Kirkland et al. 2016).
InVivoTesting
A large number of in vivo genotoxicity studies have
been conducted for benzene. As inhalation is considered
the most relevant route of exposure for this case study, we
focused on in vivo studies using this route of exposure.
The resulting findings are summarized in Table V. In trans-
genic rodent studies, exposure to benzene via inhalation
resulted only in marginal (<twofold) and inconsistent
increases in mutant frequency in the lung and spleen
(Mullin et al. 1995, 1998); however, a larger increase in
mutant frequency was observed in splenic T-cells in mice
after long exposures (up to 38 weeks) to high doses
(Albertini et al. 2010). Inhalation of benzene induced
increased levels of DNA damage in peripheral blood, bone
marrow, and liver at different doses in the in vivo comet
assay in mice (Plappert et al. 1994). Findings from in vivo
micronucleus tests (MNTs) showed a consistent response:
each of the studies identified showed an increase in MN in
bone marrow in mice (wild type and genetically modified)
and rats (Erexson et al. 1986; Luke et al. 1988; Farris et al.
1996; Healy et al. 2001; French et al. 2015). In mice,
increases in MN were also observed for peripheral blood
(Tice et al. 1989; Farris et al. 1996; French et al. 2015).
The positive results in the MNT were found after both
short- and long-term (up to 24 weeks) exposure to doses up
to 1,000 ppm (Table V). The magnitude of the response is
dependent on the duration and frequency of exposure as
well as on the sex and strain of mice. The MN response in
male mice was greater compared to females, consistent
with benzene-mediated higher carcinogenic responses in
males (Luke et al. 1988; Tice et al. 1989). It has been
suggested that this gender difference in sensitivity is
(partly) due to hormonal factors (Siou et al. 1981).
Rodent studies focused on DNA reactivity (measured
using 32P-postlabeling or DNA-binding studies) did not
suggest preferential binding of benzene or its metabolites
with rat or mice DNA in target tissues showing neoplasia.
At dose levels producing neoplasia in rodents, benzene or
its metabolites did not cause adducts in the Zymbal gland
(neoplastic target organ for benzene), liver, kidney, mam-
mary gland, or bone marrow (Whysner et al. 2004, and ref-
erences therein).
Various studies providing relevant information to better
understand the mechanisms underlying the toxicity of benzene
were identified. Studies in Cyp2e1−/− mice demonstrated once
more the key role of the CYP2E1 enzyme in benzene-
mediated toxicity, as Cyp2e1−/− mice did not exhibit geno-
toxicity or cytotoxicity in the blood, bone marrow, thymus,
and spleen, in contrast to wild-type mice (Valentine et al.
1996). The aryl hydrocarbon receptor (AhR) participates in
CYP2E1 induction and thus in benzene-mediated toxicity, as
no hematotoxicity was induced in AhR−/− mice (Yoon et al.
2003). Benzene was shown to inhibit topoisomerase II
TABLEV. Summary of in vivo Genotoxicity Findings for Benzene
Species/Strain Exposure regimen Result Reference
Gene mutation
B6C3F1 transgenic
lambda/lacI mice
300 ppm; 6 hr/day, 5 days/
week, 12 weeks
Marginal increase in mutant frequency
in lung and spleen at 300 ppm
Mullin et al.
(1995, 1998)
C57BL/6 p53+/− and
C57BL/6 WT mice
100–200 ppm; 6 hr/day, 5 days/
week, 38 weeks
Increase in mutant frequency in splenic
T-cells at 100 ppm
Albertini et al. (2010)
DNA damage (comet)
BDFI mice 100–900 ppm; 6 hr/day, 5 days/
week, six weeks
Positive in liver, peripheral blood, and
bone marrow at 100 ppm
Plappert et al. (1994)
Chromosome aberration
DO mice 1–100 ppm; 6 hr/day, 5 days/
week, 4 weeks
MN: positive in bone marrow and
peripheral blood at 1 ppm
French et al. (2015)
DBA/2 mice 10–1000 ppm; six hours MN: positive in bone marrow at
10 ppm
Erexson et al. (1986)
Sprague–Dawley rats 0.1–30 ppm; six hours MN: positive in bone marrow at 1 ppm Erexson et al. (1986)
Tg.p53+/− and Tg.AC mice and
wild-type counterparts
(FVB/N and C57BL/6)
100–200 ppm; 6 hr/day, 5 days/
week, 38 weeks
MN: positive in bone marrow at
100 ppm
Healy et al. (2001)
B6C3F1 mice 1–200 ppm; 6 hr/day, 5 days/
week, for one, two, four, or
eight weeks
MN: positive in bone marrow and
peripheral blood at 100 ppm
Farris et al. (1996)
DBA/2 mice 300 ppm, 13 weeks MN: positive in bone marrow at
300 ppm
Luke et al. (1988)
B6C3F1, DBA/2, and
C57BL/6 mice
300 ppm, 5 days/week,
13 weeks
MN: positive in peripheral blood at
300 ppm
Tice et al. (1989)
DO, diversity outbred; MN, micronuclei.
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enzyme activity in an isolated enzyme system, in a human
bone marrow-derived leukemia cell line, and in vivo in the
bone marrow of treated mice via oral gavage (Eastmond et al.
2001). The latter in vivo study also demonstrated that benzene
induces both chromosome breakage and aneuploidy, with
chromosome breakage being the predominant effect, while
aneuploidy was a relatively infrequent event (Eastmond et al.
2001). Inhibition of topoisomerase II enzyme activity was
also observed in in vitro studies testing metabolites of ben-
zene (Hutt and Kalf 1996; Lindsey Jr. et al. 2004; Eastmond
et al. 2005). The hypothesis that the genotoxic effects of ben-
zene are secondary to oxidative stress and inhibition of topo-
isomerase II was further substantiated by mechanism-oriented
transcriptomics studies in p53-knockout mice and wild-type
mice (Yoon et al. 2003; Faiola et al. 2004).
Overall, the in vivo tests for chromosome aberrations con-
firmed the positive findings observed under in vitro condi-
tions. All chromosome aberrations and MNTs evaluated for
this case study were positive. Additionally, the in vivo data
provided relevant information regarding characteristics of
benzene and the mechanisms involved in its genotoxic poten-
tial, including its capacity to induce aneuploidy. The results
obtained from the in vivo gene mutation tests are in line with
the poor evidence for benzene’s potential to induce gene
mutations in vitro: The data collected suggest this potential is
very weak and is only detected when using large cumulative
doses (time × concentration). This is consistent with increas-
ing evidence that gene mutations can also be induced as a
consequence of primary toxicity (eg, inflammatory processes)
(Wickliffe et al. 2016) rather than direct DNA reactivity.
Consequently, the weight-of-evidence of available data for
benzene supports a conclusion that benzene is predominantly
a clastogenic as well as aneugenic substance.
Other Relevant Toxicity Data
Like for any other toxicological effect, the potential/
potency of a substance to induce genetic toxicity or genomic
damage is not evaluated in isolation. Information obtained
from toxicity studies targeting other endpoints can be very
useful to better understand the mode(s) of action involved, in
particular when these appear to be fairly complex. Ideally,
when available, human studies should be carefully evaluated
during a risk assessment. However, as mentioned before, data
from human studies were not considered in this benzene case
study because this type of study would normally not be avail-
able for a new substance under evaluation.
For benzene, information obtained from repeated-dose
toxicity studies and reproductive toxicity studies in experi-
mental animals is considered relevant when assessing geno-
mic damage. These animal studies have shown that
benzene has the potential to induce toxicity in the hemato-
logical system, including significantly reduced counts of
erythrocytes, leukocytes, and platelets and other evidence
of adverse effects on blood-forming units (ATSDR 2007;
ECHA 2018). Adverse immunological effects in response
to inhalation exposure of benzene have also been observed
in animal studies. The effects include damage to both
humoral (antibody) and cellular (leukocyte) responses
(ATSDR 2007), which was shown in animal studies to
result in impaired cellular immunity (ECHA 2018).
Regarding reproductive toxicity, effects on fertility and
development have been observed in animals only at very
high doses (ECHA 2018).
Mode ofAction
Epidemiological data on benzene link high levels of ben-
zene exposure, among other effects, to various forms of
leukemias and cytogenetic effects (ECHA 2018). The data
collected in the previous sections inform that the metabo-
lism of benzene is inherently complex and results in the
formation of numerous reactive and toxic metabolites as
well as reactive oxygen species. Benzene has the ability to
induce chromosomal damage, which seems a plausible
mode of action (MOA) for its carcinogenicity through
interaction of its metabolites with macromolecules of target
cells. Benzene has weak potential to induce gene mutations
and primary DNA reactivity of benzene and/or its metabo-
lites seems of little importance in relation to carcinogenesis.
The genotoxic effects of benzene are suggested to be sec-
ondary to oxidative stress and inhibition of topoisomerase
II (Yoon et al. 2003; Faiola et al. 2004), that is, nonlinear
mechanisms. Benzene and/or its metabolites are also
known to alter cell proliferation (Meek and Klaunig 2010)
and thus provide an environment for the proliferation of
genetically initiated cells, eventually leading to tumors.
This abridged MOA based on the genetic toxicity data
alone is consistent with that proposed by Meek and
Klaunig (2010) taking into consideration other known bio-
logical effects of benzene. The latest International Agency
for Research on Cancer monograph (IARC 2018) con-
cluded that benzene, in addition to being genotoxic,
exhibits many of the key characteristics of carcinogens as
described by Smith et al. (2016). These include its ability
to (1) become electrophilic upon metabolic activation,
(2) alter DNA repair processes, (3) induce genomic insta-
bility, (4) alter the epigenome, (5) suppress the immune
system, (6) induce oxidative stress, (7) alter cell prolifera-
tion, and (8) modulate receptor-mediated effects, in particu-
lar the AhR. This is supported by studies investigating the
mechanisms by which benzene affects hematopoietic stem
cells to cause toxicity and cancer (McHale et al. 2012;
Wang et al. 2012; Li et al. 2018). Thus, there is growing
evidence that benzene is acting via multiple pathways in
eliciting its tumorigenic response, although most of the key
characteristics listed above are not independent of each
other. An alternate explanation might be that a clear under-
standing on its MOA is still elusive. Despite the many
mechanisms benzene can influence, the quantitative
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analyses in the next session focuses, for illustration of the
framework, on genotoxicity only.
QuantitativeAnalyses
One of the goals of the framework is to quantify the risk
of substances that induce genomic damage on the basis of
experimental data. Given that we consider benzene a pre-
dominantly clastogenic and aneugenic substance, data on
MN induction were considered appropriate for quantitative
analyses to assess genotoxicity. Again, such a quantitative
analysis should ideally be conducted using data from
human studies. However, human studies often vary greatly
in quality, for example, with regard to accuracy of expo-
sure assessment and control for confounding factors
(ECHA 2018). Moreover, this type of study would nor-
mally not be available for a new substance to be evaluated.
Therefore, for the purpose of this case study we chose to
use MN data from a data-rich NTP/National Institute of
Environmental Health Sciences study conducted in Diver-
sity Outbred (DO) mice (French et al. 2015). Although this
study is not fully compliant with OECD Test Guideline
474 (OECD 2016), especially in terms of genotype and
number of animals used per dosing group, we consider this
study useful to illustrate how quantitative analysis of data
on genetic damage could be employed for risk assessment.
DO mice are genetically heterozygous and carry a com-
plex mixture of alleles; hence, these mice have been
suggested to mimic interindividual variation in humans
(French et al. 2015). The study involved benzene exposure
(0, 1, 10, or 100 ppm) of male DO mice (75 animals/expo-
sure group) via inhalation for 28 days (six hours/day for
five days/week). Measurements of chromosomal damage
included MN frequencies in reticulocytes (RETs) from
bone marrow. We analyzed these data using the advanced
combined covariate benchmark dose (BMD) approach,
which generally improves the precision in the estimated
BMDs (Slob 2002; Slob and Setzer 2014). This approach
requires multiple data sets that are comparable with respect
to the endpoint, tissue, and route of exposure; thus, dose–
response data from a similar experiment in B6C3F1 mice
were also used (Farris et al. 1996). Quantitative analysis
using the BMD approach also requires specification of a
predefined fractional increase in response above the concur-
rent control, a value commonly referred to as the bench-
mark response (BMR) or critical effect size (CES). For
continuous data, the EFSA recommended default value for
a CES (BMR) is 5%, but the effect size “may be modified
based on statistical or toxicological considerations” (EFSA
2009). For the quantitative analysis of data on genotoxicity,
which is a recent development, initially a CES of 10% was
used (MacGregor et al. 2015a, 2015b; Wills et al. 2016a,
2016b; Long et al. 2018). However, two subsequent ana-
lyses have shown independently that a CES value of 50%
would be more appropriate for genetic toxicity data such as
those obtained from the in vivo MN test (Slob 2017; Zeller
et al. 2017). Therefore, combined covariate BMD analysis
of the two data sets was performed using a CES of 50% at
which the response constitutes an increase deemed appro-
priate for this endpoint. To note, unlike tumor data, gen-
otoxicity data are considered continuous data like, for
example, body weight. This analysis, which was performed
in PROAST (version 65.5; http://www.proast.nl) with
strain as the covariate, resulted in a BMC50 of 11.4 ppm
benzene for DO mice, with 9.6 ppm and 14.2 ppm as the
lower (BMCL50) and upper (BMCU50) confidence limits,
respectively (Fig. 1). In a risk assessment, this BMC50,
including its confidence limits, can be used as a PoD for
assessing human risk associated with genomic damage.
EstimateAcceptable Levels for Endpoints of Human
Relevance
The next step in the framework is to estimate the accept-
able level of a daily exposure to the human population
(including vulnerable subgroups) that is likely to be with-
out an appreciable risk of deleterious effects during a life-
time (USEPA 2015). Focusing on the genotoxic damage
(the observed clastogenic and aneugenic effects) by ben-
zene that is considered secondary in nature (see the “Mode
of Action” section), a traditional risk assessment using
assessment factors can be applied to determine the accept-
able level of daily exposure as described later (DECOS
2014; AGS 2016; ECHA 2018).
An acceptable level of a daily exposure to the human
population is determined by extrapolating from the PoD of
the key experimental data set by correcting for uncertainty
through the use of assessment factors (AFs). While the AFs
applied do vary across regulatory jurisdictions and geo-
graphical regions, they conceptually agree in that the com-
bined AFs are thought to account for all (various) sources
of uncertainty. Typically, a composite or total AF of 100 is
derived by multiplying a factor of 10 for animal to human
extrapolation (interspecies) and a factor of 10 for variability
within human populations (intraspecies). These AFs can be
adjusted based on various considerations, including species
differences and allometric scaling or differences in absorp-
tion, distribution, metabolism, and pharmacokinetics. Addi-
tional AFs are sometimes used to account for differences in
the duration and/or frequency of exposure, severity of tox-
icity endpoint, and uncertainty in the PoD (MacGregor
et al. 2015a). It is important to mention that the use of AFs
to extrapolate from genotoxicity data is a new area and
there is ongoing discussion in the expert community but no
agreement to date as to what AFs to use in this context.
The use of AFs serves the purpose of illustrating how this
can work in practice but should not be seen as setting a
precedent in this respect. We highly encourage further dis-
cussion in this area.
Environmental and Molecular Mutagenesis. DOI 10.1002/em
105Evaluation of a New Framework for Genomic Damage
For the benzene case study, the first step is to correct the
PoD for differences between the exposure regimen used for
the animal study and the likely human exposure scenario.
There are multiple approaches to achieve this; here, we per-
formed the same calculations as done by RAC (ECHA
2018). DO mice were exposed for six hours/day, whereas
workers are assumed to be exposed for eight hours/day.
Furthermore, workers are assumed to have a relatively
enhanced breathing pattern compared to animals because of
a higher level of activity. This leads to a theoretical
increase in the volume of inhaled air over eight hours from
a human-equivalent volume of 6.7 m3 to 10 m3 (ECHA
2012). Hence, the BMCL50 and BMDU50 values of
9.6 ppm and 14.2 ppm, respectively, derived from the DO
mouse study would translate to a human-equivalent PoD
range of 4.8 ppm to 7.1 ppm (i.e., animal PoD * (6/8 *
6.7/10)). As a next step, AFs would be applied to derive an
acceptable range of a daily exposure to the human popula-
tion. The AFs chosen to be applied in this case study
include factors for intraspecies and interspecies extrapola-
tion (interspecies variability in toxicokinetics and
toxicodynamics), study duration, and effect severity. Even
for endpoints that have a much longer history of use of risk
quantification methods, there is no globally harmonized
approach to which AFs (type and value) should be used;
this depends on the nature of the regulatory purpose and
the regulatory jurisdiction.
For illustrative purposes only, we have determined the
acceptable range of a daily exposure to workers and to the
general population in Europe. For workers, we applied
the same AFs as used by RAC, where appropriate (ECHA
2018). According to the RAC opinion, appropriate AFs
would include an AF of 2.5 to account for interspecies var-
iability in toxicokinetics and toxicodynamics and an AF of
6 to extrapolate the findings from a 28-day animal study to
a chronic exposure. For intraspecies variability an AF of
5 would apply, plus an additional AF of 3 to account for
the severity of the effect (ECHA 2018). In this example,
application of a composite AF of 225 (2.5*6*5*3) to the
human-equivalent PoD range of 4.8–7.1 ppm would result
in an acceptable range of a daily exposure of 21–32 ppb
for workers. For the determination of an acceptable range
of a daily exposure for the general population in Europe,
we followed ECHA guidance (ECHA 2012). For this
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Fig. 1. Benzene genotoxic potency values determined for DO and
B6C3F1 mice using BMD analyses with strain as covariate. The
response (Y-axis) metric is MN frequency in bone marrow-derived
reticulocytes in %, and the X-axis metric is airborne benzene
concentration in ppm. Data were fitted with the exponential continuous
data model (left panel) and the Hill model (right panel) using a CES of
50%. The data shown in black indicate the B6C3F1 response; red shows
the DO response. Values shown are means with confidence intervals as
standard deviation. The text adjacent to each panel provide curve fit
parameters (i.e., AIC and log likelihood), mean background for each
levels of the covariate (i.e., parameter a), BMD values (i.e., CED or
Critical Effect Dose), estimated maximum response and log steepness
(i.e., parameters c and d), and BMD (CED) confidence lower and upper
confidence limits.
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population group, exposure is not necessarily limited to
working hours but may occur throughout the day; in a
worst-case scenario this could be 24 hr. On the other hand,
the overall level of activity could be assumed to be similar
between the general population and the animals in the
respective study. Based on these assumptions, the BMCL50
and BMDU50 values of 9.6 ppm and 14.2 ppm derived
from the DO mouse study would translate to a human-
equivalent PoD range of 2.4 ppm to 3.6 ppm (i.e., animal
PoD * 6/24). The same AFs as used for workers can apply,
except for the AF for intraspecies variability; an AF of
10 instead of 5 was considered more appropriate as a
higher variability is expected in the general population ver-
sus industry workers. Together, this would result in a com-
posite AF of 450 (2.5*6*10*3), leading to an acceptable
range of a daily exposure of 5.3–8 ppb for the general pop-
ulation. These values for acceptable levels of a daily expo-
sure are examples and may change depending on
agreements of the expert community. For instance, there is
currently no consensus regarding the need of an additional
AF that accounts for effect severity. An AF of 3–10 would
be consistent with recommendations by ECHA and by ICH
for oncogenic effects (ECHA 2012, 2018; ICH 2016).
Also, the AF used to account for study duration is based on
the assumption that the effects observed after 28 days need
adjustment when extrapolated to lifetime exposure, which
may not be supportable for the endpoint used
(clastogenicity and aneugenicity as measured in the micro-
nucleus assay). Micronucleus formation is an acute
response to the exposure that reaches a steady state
(MacGregor et al. 1990) and exposure times beyond acute
can be used but not required as defined in OECD guideline
474 and the assay has shown similar sensitivity for acute
and subchronic exposures (Witt et al. 2000).
RiskCharacterization
To determine if humans are at risk, the dose at which a
hazard (toxicity) occurs is compared with exposure estimates
for every specific scenario. For this, as described in our
framework for next generation risk assessment of genomic
damage (Dearfield et al. 2017), one may apply the margin of
exposure (MOE) approach that was developed by EFSA for
substances that are both genotoxic and carcinogenic (EFSA
2005). As benzene’s genotoxic activity is considered second-
ary in nature, we have not applied the MOE concept for ben-
zene but focus on the outcome of the traditional risk
assessment detailed in the previous section. In our example
following the approach taken by ECHA’s RAC, the accept-
able range of a daily exposure to benzene was 21–32 ppb for
workers, whereas the long-term average exposure levels esti-
mated for workplaces in Europe is in the range of
50–100 ppb (0.05–0.1 ppm). For the general population, we
determined in our example an acceptable range of a daily
exposure of 5.3–8 ppb for genetic damage. As laid out in the
“Exposure Assessment” section, the limit value for air con-
centrations in the European Union is set at 5 μg benzene/m3
(1.5 ppb) for all effects of benzene (EC 2008b). It should be
noted that the assumption that the public would inhale air
containing this limit concentration of 1.5 ppb for 24 h a day,
over a lifetime, is very conservative.
We would like to stress that the aforementioned examples
for workers and the general population are a simplification,
as reflected by using the limit value for air concentrations in
the European Union as a daily exposure estimate for the gen-
eral population. Additionally, other aspects such as availabil-
ity of personal protection equipment and exposure from
smoking and refueling were not considered. Daily exposure
estimates would increase for smokers, as smoking is consid-
ered a substantial contributor to benzene exposure (Wallace
1989; Arnold et al. 2013). Thus, the examples are provided
solely to illustrate how the framework could be applied as a
contribution to a comprehensive risk assessment. In general,
risk managers consider aspects such as the context of use,
availability of personal protection equipment, the severity of
the effect, the toxicological mechanisms involved, the num-
ber of assumptions used, and the size of the affected popula-
tion when evaluating the risk. This will affect the risk
management decision if the risks can be considered accept-
able or need to be decreased, for example, by measures to
reduce exposure.
EVALUATIONANDCONCLUSIONS
The purpose of this case study was to evaluate the utility of
the framework we developed for assessing the risk of genomic
damage due to exposure to chemical substances. Ideally, we
would have applied the framework in a prospective approach
where testing outcome and human health consequences were
unknown. This is quite challenging for a data-rich substance
like benzene, and would have required additional measures
such as a blinded setup of the case study. Therefore, we
employed a retrospective approach for this case study.
To evaluate the framework, we reviewed all the informa-
tion and data collected, taking into account the anticipated
exposure category determined in the planning and scoping
phase. The qualitative categorization of the likely exposure
scenarios is intended as a screening tool for setting priori-
ties (Dearfield et al. 2017). For workers, the anticipated
exposure category was “minimal” (“Planning and Scoping”
section). Therefore, it was concluded that a limited data set
may be considered if focusing solely on workers: Predic-
tions of human exposure levels for the most likely exposure
scenario, cheminformatics (in silico predictions) indicating
complex metabolic processes may be involved and info-
rming on possible genotoxicity testing outcomes, in vitro
genotoxicity testing providing alerts for clastogenicity and
aneuploidy, and an in vivo MNT confirming clastogenic
and possibly aneugenic effects. The latter would also serve
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as a source for deriving PoDs and acceptable levels, to
allow for risk characterization. It should be noted that the
in silico predictions for benzene and the five analogs them-
selves could be interpreted incorrectly as “negative,” if the
indirect alerts stemming from reactive metabolites were not
taken into account. Given that benzene is used primarily as
a synthesis intermediate and measures are in place to pro-
tect workers from benzene exposure, extensive investiga-
tions to unravel all details of the mechanism(s) underlying
cancer are not considered directly necessary if workers
would have been the only population group of concern. It
should be noted, however, that also possible incidents
impacting production facilities and their immediate envi-
ronment need to be included in a risk assessment. Further-
more, investments in understanding the mechanisms of
toxicity involved are worthwhile, as these data can be
reused for substances that have a similar MoA.
For the general population, the situation would be some-
what different because wide exposure was anticipated.
Because of the probable increased concern due to the
anticipated high number of exposed individuals, additional
investigation into the relevance to human risk is called for
in the framework. Therefore, more robust and appropriate
exposure assessments and toxicity testing would likely be
required. These may include more detailed exposure assess-
ments (eg, addressing effects of nonexposed periods on
toxicity and the influence of short-term high exposures),
leading to better insight into internal exposure levels. All
of the data and information analyzed in this retrospective
case study show what would likely have occurred in a pro-
spective approach in a similar scenario. Furthermore,
besides the information described earlier for the worker
population, better insight into the ADME properties of ben-
zene, including identification of a number of metabolites,
some of which can react with macromolecules such as
DNA, and more detailed understanding of the involved
MOAs would have been required for a proper assessment
of the genotoxic potential. Some understanding of the
MOA would have been achieved with the information col-
lected (in case a prospective approach was taken), but it is
clear that this step in the framework is critical to highlight
the need for possible additional actions/investigations to
investigate genomic damage. In our view, although not dis-
cussed here in detail, the adverse outcome pathway (AOP)
concept (Ankley et al. 2010; OECD 2013) could also be
used to ensure better understanding of the mechanisms
involved. This would also support the use of targeted tests
rather than a prescribed set of assays as is customary in
some regulatory settings. Increased understanding of bio-
logical pathways triggered by a chemical can provide
mechanistic insights that support the understanding of the
relevance of (genotoxic) effects to human risk assessment.
Such enhanced understanding is also key for selecting key
events (and thus studies) to be used for quantitative ana-
lyses and PoD determination. In the case of benzene, it
seems plausible that multiple mechanisms (ie, a network of
pathways) are involved in carcinogenesis. Delineating this
network, including identification of key events and quanti-
fication of their relationships, would be highly valuable to
determine whether a PoD based on genetic damage is the
most appropriate key event or perhaps overly conservative.
The benzene case study confirmed once more that the
outcome of a risk assessment is also driven by its purpose:
The assessment for workers yielded different safety mar-
gins compared to the assessment done for the general popu-
lation. In our example, this difference in safety margins
was partly attributed to the anticipated larger variability
within the general population. However, the same level of
variability could be seen, by chance, in a worker popula-
tion. Another factor explaining the difference in safety mar-
gins is the difference in the exposure estimates between the
population groups, and it has to be emphasized that the
assumption of a daily exposure at the defined upper limit
of benzene content in ambient air over lifetime for the gen-
eral population seems highly conservative. The large
impact of the exposure estimation on the calculations
underpins the need for robust exposure assessment which
currently is often lacking.
Another element that should be addressed with sufficient
care is toxicokinetics, because each of the ADME compo-
nents is highly relevant for exposure estimation and risk
assessment. For example, information on elimination indi-
cated the accumulation of benzene, whereas knowledge on
the complexity of benzene metabolism appeared to be
essential for the interpretation of both in silico findings and
test results from in vitro systems, as well as understanding
of the mechanisms underlying genetic damage. Further-
more, insight into toxicokinetic properties contributes to
proper assessment of interindividual variability in suscepti-
bility of adverse health outcomes. The relevance of knowl-
edge on metabolic processes involved was also apparent
from the results obtained with cheminformatics, that is, the
(Q)SARs and read-across/analog identification methods.
Besides the likelihood of a metabolite to be formed in vivo,
the software tools used indicated alerts for in vitro
clastogenicity of secondary metabolites of benzene. This
nicely demonstrates the benefit of using these tools in an
early phase of an assessment: Besides information on
potential hazard, the predictions for benzene also point to
careful consideration of metabolic competency of the
in vitro tests to be used. These additional information
requirements on exposure and toxicokinetics clearly exceed
the current information requirements (at least for industrial
chemicals in the EU), especially as the amount of available
information for benzene is already much larger than for
most other substances.
Finally, it was ascertained that application of the frame-
work requires integration of different areas of expertise.
Although this holds also true for the risk assessment
approaches currently in place, it was considered
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increasingly relevant due to the flexible nature of the new
approach. Consequently, intensified interdisciplinary col-
laborations may be required. A more flexible approach is
expected to increase cost efficiency compared to traditional
approaches to chemical hazard characterization. On the
other hand, external and internal exposure assessments may
increase the assessment cost. A drawback of the framework
could be that it is more difficult to predict the total cost of
hazard identification, exposure quantification, and risk
assessment; however, this may be partly resolved by an
accurate and detailed problem formulation.
Taken together, this case study provides proof-of-principle
that the next generation framework for assessment of geno-
mic damage is a useful contribution to a comprehensive risk
assessment. The framework enabled a more efficient risk
assessment process by providing all elements needed for
decision making in a systematic manner. Also, the flexibility
inherent in the approach fueled broader thinking and the gen-
eration of more information for a fuller understanding of
potential human risk. Although there is a great amount of
data on benzene available as can be seen in the retrospective
analysis here, inserting this into the framework in a prospec-
tive way demonstrated the utility of this next generation
framework. Additional case studies, both for other industrial
chemicals and other types of products, would be useful to
further refine the approach. Preferably, these future case stud-
ies would incorporate aspects of next generation risk assess-
ment that were not (sufficiently) addressed in the present
case study, such as application of the AOP concept to guide
toxicity testing and the organization of mechanistic informa-
tion, addressing genomic (including epigenetic, and not only
genetic) damage, and have greater emphasis on the use of
non-animal methods for toxicity testing. Such case studies
are expected to further improve the framework, which we
believe has shown to be useful for the benzene case, thereby
contributing to achieve next generation risk assessment.
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